Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing
Fabienne Lucas, Phillip Michaels, Dahai Wang, Annette S. Kim
Abstract
Key Points Findings support use of PB samples for chronic myeloid neoplasms and for acute leukemias with sufficient circulating disease. In acute leukemias, BM appears to be superior to PB for monitoring measurable residual disease, even in the absence of BM excess blasts.
Topics & Concepts
Bone marrowMinimal residual diseaseMedicineHematologic NeoplasmsMyeloidPeripheral bloodMyeloid leukaemiaHematologic diseasePathologyHematologic disordersPeripheralMyeloid leukemiaDiseaseImmunologyInternal medicineCancerAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentCancer Genomics and Diagnostics